…
Delta 9 Cannabis Inc., together with its subsidiaries, operates as an integrated cannabis company. The company engages in the cultivation, processing, extraction, wholesale distribution, retail, and sale of medical and recreational cannabis products. Its products include dried cannabis flowers, pre-rolls, and dried sift cannabis, as well as oils, and extracted and derivative products. The company also offers grow pods and live plants to other licensed and pre-licensed companies. In addition, it operates as a medical clinic that provides physician consultation services to patients seeking a medical recommendation for a cannabis prescription. The company operates retail stores under the Delta 9 brand name across the Canadian provinces. It also exports its products to Australia. Delta 9 Cannabis Inc. was incorporated in 2001 and is based in Vancouver, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -27.84M | -11.54M | -5.08M | 13.52M | -8.58M |
| Minority interest | 0.64M | -0.04M | 0.93M | -0.01M | -0.15M |
| Net income | -28.11M | -11.14M | -5.49M | 31.15M | -8.49M |
| Selling general administrative | 19.21M | 8.49M | 9.35M | 9.77M | 9.60M |
| Selling and marketing expenses | 0.66M | 10.58M | 6.62M | 4.83M | 2.08M |
| Gross profit | 10.88M | 17.32M | 18.00M | 16.40M | 5.74M |
| Reconciled depreciation | 7.97M | 6.48M | 5.31M | 3.55M | 0.96M |
| Ebit | -20.26M | -7.64M | -2.08M | -2.07M | -8.50M |
| Ebitda | -12.45M | -1.17M | 3.24M | 1.47M | -7.52M |
| Depreciation and amortization | 7.81M | 6.47M | 5.31M | 3.55M | 0.99M |
| Operating income | -20.26M | -7.64M | -2.08M | -2.07M | -8.50M |
| Other operating expenses | 83.49M | 69.93M | 54.81M | 33.97M | 16.07M |
| Interest expense | 6.51M | 3.90M | 3.20M | 1.81M | 0.11M |
| Tax provision | 0.00M | -0.40M | 0.40M | 0.00M | - |
| Interest income | 3.12M | 3.35M | 0.04M | 1.63M | 0.12M |
| Net interest income | -6.98M | -4.27M | -3.15M | -1.76M | 0.12M |
| Income tax expense | 0.28M | -0.40M | 0.40M | -17.63M | -0.10M |
| Total revenue | 63.23M | 62.29M | 52.05M | 31.77M | 7.57M |
| Total operating expenses | 31.14M | 24.96M | 20.77M | 18.60M | 14.24M |
| Cost of revenue | 52.35M | 44.97M | 34.05M | 15.36M | 1.83M |
| Total other income expense net | -7.58M | -3.90M | -3.01M | 15.59M | -0.08M |
| Net income from continuing ops | -27.84M | -11.14M | -5.49M | 13.52M | -8.58M |
| Net income applicable to common shares | -27.20M | -11.18M | -6.42M | 13.74M | -8.49M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 89.55M | 74.78M | 76.40M | 66.16M | 45.98M |
| Intangible assets | 0.00M | 0.15M | 0.15M | - | - |
| Other current assets | 0.38M | 0.30M | 0.15M | 0.18M | 0.32M |
| Total liab | 83.01M | 49.50M | 41.56M | 31.73M | 10.67M |
| Total stockholder equity | 6.56M | 24.67M | 35.00M | 34.44M | 35.46M |
| Other current liab | 12.43M | 7.99M | 8.54M | 4.53M | 0.39M |
| Common stock | 72.58M | 64.08M | 53.16M | 55.38M | 53.16M |
| Capital stock | 72.58M | 64.08M | 53.16M | 55.38M | 53.16M |
| Retained earnings | -54.57M | -27.37M | -21.60M | -7.39M | -21.14M |
| Other liab | - | 1.19M | 1.17M | - | - |
| Good will | 14.20M | 2.91M | 0.66M | - | - |
| Other assets | - | 0.27M | 0.51M | - | 2.76M |
| Cash | 3.52M | 0.94M | 8.08M | 5.85M | 16.23M |
| Total current liabilities | 52.81M | 40.30M | 15.77M | 11.40M | 5.75M |
| Current deferred revenue | 0.60M | 0.56M | 0.45M | 0.22M | 0.12M |
| Net debt | 62.62M | 35.76M | 27.65M | 23.03M | -10.84M |
| Short term debt | 37.26M | 28.70M | 9.20M | 8.54M | 0.48M |
| Short long term debt | 29.81M | 11.34M | 0.15M | 0.64M | 0.53M |
| Short long term debt total | 66.14M | 36.71M | 35.73M | 28.87M | 5.39M |
| Other stockholder equity | 7.83M | 7.23M | 3.44M | 5.49M | 4.58M |
| Property plant equipment | 47.42M | 40.21M | 41.60M | 37.00M | 16.77M |
| Total current assets | 27.20M | 30.72M | 32.52M | 27.97M | 26.38M |
| Long term investments | 0.53M | 0.53M | 0.93M | 1.15M | 2.76M |
| Net tangible assets | - | 21.62M | 31.17M | 34.39M | 35.39M |
| Net receivables | 2.57M | 5.64M | 5.37M | 5.56M | 2.03M |
| Long term debt | 15.59M | 2.48M | 22.93M | 18.51M | 4.92M |
| Inventory | 19.82M | 22.59M | 17.86M | 14.96M | 6.35M |
| Accounts payable | 2.53M | 3.05M | 1.85M | 0.37M | 4.77M |
| Accumulated other comprehensive income | -19.27M | -19.27M | - | -19.04M | -1.14M |
| Common stock total equity | - | - | - | 55.38M | 53.16M |
| Non currrent assets other | 0.20M | 0.27M | 0.51M | 38.19M | 19.60M |
| Non current assets total | 62.35M | 44.06M | 43.88M | 38.19M | 19.60M |
| Capital lease obligations | 20.74M | 12.17M | 10.69M | 8.58M | - |
| Long term debt total | 28.88M | 8.01M | 26.53M | 20.33M | 4.92M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -13.87M | 0.89M | 0.89M | -14.07M | -20.52M |
| Change to liabilities | - | 5.80M | 4.28M | -2.30M | 4.78M |
| Total cashflows from investing activities | -13.87M | -2.86M | -6.32M | -14.07M | -20.52M |
| Net borrowings | - | -4.10M | 2.13M | 14.60M | 5.39M |
| Total cash from financing activities | 16.80M | -3.50M | 7.04M | 15.81M | 22.03M |
| Change to operating activities | - | -0.96M | -0.44M | 0.25M | -1.29M |
| Net income | -27.84M | -11.14M | -5.49M | 13.52M | -8.58M |
| Change in cash | -0.72M | -7.13M | 2.23M | -10.38M | -7.32M |
| Begin period cash flow | 4.24M | 8.08M | 5.85M | 16.23M | 23.55M |
| End period cash flow | 3.52M | 0.94M | 8.08M | 5.85M | 16.23M |
| Total cash from operating activities | -3.66M | -0.78M | 1.51M | -12.13M | -8.83M |
| Issuance of capital stock | 1.72M | 0.00M | 5.01M | 1.15M | 16.71M |
| Depreciation | 7.97M | 6.48M | 5.31M | 3.55M | 0.96M |
| Other cashflows from investing activities | -11.50M | -0.28M | -0.48M | -0.03M | -3.00M |
| Change to inventory | 1.58M | -5.67M | -6.42M | -2.23M | -2.12M |
| Change to account receivables | 1.80M | 0.49M | 0.45M | -3.70M | -1.71M |
| Sale purchase of stock | 1.72M | 0.00M | 5.01M | 1.15M | 16.71M |
| Other cashflows from financing activities | 46.49M | 1.11M | 5.73M | 16.78M | 5.40M |
| Change to netincome | - | 4.68M | 4.30M | -21.44M | -0.96M |
| Capital expenditures | 2.36M | 2.58M | 5.84M | 14.03M | 17.52M |
| Change in working capital | 7.62M | -0.75M | -1.69M | -7.98M | -0.34M |
| Stock based compensation | 1.62M | 1.46M | 1.62M | 1.44M | 2.62M |
| Other non cash items | 6.97M | 3.18M | 1.75M | -22.66M | -3.49M |
| Free cash flow | -6.02M | -3.35M | -4.33M | -26.16M | -26.35M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CURA Curaleaf Holdings Inc. |
1.23 9.59% |
14.06 | - | 138.89 | 2.57 | 3.14 | 2.47 | 13.10 |
| BHC Bausch Health Companies Inc |
0.12 1.07% |
11.37 | 13.98 | 1.35 | 0.28 | 18.74 | 2.12 | 6.84 |
| CRON Cronos Group Inc |
0.06 1.28% |
4.76 | - | 32.15 | 9.80 | 0.95 | 1.47 | 1.90 |
| TLRY Tilray Inc |
0.13 3.66% |
3.68 | - | 1000.00 | 1.28 | 0.53 | 1.08 | -2.30 |
Delta 9 Cannabis Inc., together with its subsidiaries, operates as an integrated cannabis company. The company engages in the cultivation, processing, extraction, wholesale distribution, retail, and sale of medical and recreational cannabis products. Its products include dried cannabis flowers, pre-rolls, and dried sift cannabis, as well as oils, and extracted and derivative products. The company also offers grow pods and live plants to other licensed and pre-licensed companies. In addition, it operates as a medical clinic that provides physician consultation services to patients seeking a medical recommendation for a cannabis prescription. The company operates retail stores under the Delta 9 brand name across the Canadian provinces. It also exports its products to Australia. Delta 9 Cannabis Inc. was incorporated in 2001 and is based in Vancouver, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. John William Arbuthnot IV | Co-Founder, CEO & Director | 1990 |
| Mr. John William Arbuthnot III | Co-Founder & Director | 1954 |
| Mr. James Lawson | CFO, Controller & Sec. | 1952 |
| Mr. Mark Jonker | Chief Operations Officer | NA |
| Mr. Matthew Sodomsky | Chief Technology Officer | NA |
| Mr. Derek Reimer | VP of Compliance | NA |
| Mr. Marshall Posner | Chief Marketing Officer | NA |
| Dr. David M. Kideckel M.B.A., MBA, Ph.D. | Exec. VP and Head of Strategy, Corp. Devel. & Capital Markets | 1980 |
| Mr. Ian Chadsey | VP of Corp. Affairs | NA |
| Ms. Alexa Goertzen | Sr. Exec. Assistant | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.